Cabaletta Bio Inc CABA Fundamentals and Key Ratios

Cabaletta Bio Inc. (CABA) Fundamentals


Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAAR, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CAAR T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T cell technology that is marketed for the treatment of B cell cancers.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAAR, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CAAR T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T cell technology that is marketed for the treatment of B cell cancers.

SHARE INFORMATION
Market Cap	$ 324,045,807
Shares Outstanding	29,140,810
Float	27,675,878
Percent Float	94.97%
Short Interest	0.00
Short Percent Float	0.0%
Short Interest Ratio	0.00
Short Interest Date	-
Latest Fiscal Dividend Per Share	$ 0.00
Latest Fiscal Revenue	$ 0
Latest Fiscal EPS	$ -1.80
Latest Fiscal Date	2021-12-31

DIVIDENDS
Dividend (3 Years)	$ 0.00
Dividend (5 Years)	$ 0.00
Ex Dividend Date	-
Dividend Rate	$ 0.00
Dividend Yield	0.0%
Payment Cash	-

HOLDERS
Institutions	121
Institutional Holdings Date	2022-12-31
Institutional Bought Previous 3 Months	1,296,984
Institutional Holdings Percent	53.2%
Institutional Sold Previous 3 Months	2,956,712
Insider Holdings Date	2022-12-31
Insider Bought Previous 3 Months	366,000
Insider Holdings Percent	4.1
Insider Sold Previous 3 Months	-
Insider Shares Owned	1,193,627

TRADING INFO
52 Week High	$ 11.97
52 Week Low	$ 0.59
52 Week High Change	$ 291.55
21 Day Moving Average	$ 9.799
21 Day Extended Moving Average	$ 9.6923
50 Day Moving Average	$ 7.0188
50 Day Extended Moving Average	$ 7.5218
200 Day Moving Average	$ 2.7349
200 Day Extended Moving Average	$ 4.396
10 Day Average Volume	840,132
20 Day Average Volume	788,412
30 Day Average Volume	910,651
50 Day Average Volume	939,278
Alpha	0.052995
Beta	2.4532
Standard Deviation	0.466117
R2	0.098535
7 Day Price Change	$ 0.03
7 Day Percent Change	0.27%
21 Day Price Change	$ 0.55
21 Day Percent Change	5.2%
30 Day Price Change	$ 2.64
30 Day Percent Change	31.13%
Month to Date Price Change	$ 1.87
Month to Date Percent Change	20.22%
Quarter to Date Price Change	$ 1.87
Quarter to Date Percent Change	20.22%
180 Day Price Change	$ 9.80
180 Day Percent Change	742.42%
200 Day Price Change	$ 9.51
200 Day Percent Change	590.68%
Year to Date Price Change	$ 1.87
Year to Date Percent Change	20.22%

PROFITABILITY
EBIT Margin	0.0%
EBITDA Margin	0.0%
Pre-Tax Profit Margin	0.0%
Profit Margin Count	0.0%
Gross Margin	0.0%
Profit Margin TOT	0.0%

INCOME STATEMENTS
Revenue	$ 0
Revenue Per Share	$ 0.00
Revenue (3 Years)	$ 0.00
Revenue (5 Years)	$ 0.00

FINANCIAL STRENGTH
Price to Tangible Book	4.00
Total Debt To Equity	0.00
Int Coverage	0.00
Current Ratio	15.20
Leverage Ratio	1.10
Quick Ratio	14.80
Long Term Debt To Capital	0.00

VALUATION MEASURES
PE Ratio	-6.60
Enterprise Value	$ 256,509,517
Price to Sales	0.00
Price to Free Cash	-9.40
PE High Last 5 Years	0.00
Price To Book	4.00
Price To Cash Flow	0.00
PE Low Last 5 Years	0.00
Price to Tangible Book	4.00

MANAGEMENT EFFECTIVENESS
Receivables Turnover	0.00
Invoice Turnover	0.00
Assets Turnover	0.00
Return Assets	-47.75
Return on Equity	-50.54
Return on Capital	-51.09

PROFILE INFO
Issue Type	CS
SEC Type	-
Auditor	Ernst & Young LLP
CEO	Steven Nichtberger
Emplyoees	57
Last Audit	UQ
CIK	0001759138
Industry	Biotechnology
Sector	Healthcare
NAICS	Pharmaceutical Preparation Manufacturing(325412)

CONTACT INFO
Address	2929 Arch Street Suite 600 Philadelphia, PA 19104
Website	https://www.cabalettabio.com
Facsimile	-
Telephone	+1 267 759-3100
Email	investors@cabalettabio.com

Quotes:

IHub:

CABA

Cabaletta Bio Inc. (CABA) Fundamentals

Cabaletta Bio Inc. (CABA) Key Ratios

Cabaletta Bio Inc. (CABA) Profile